Buscar Close Search
Page Menu

Sharon Cantor, PhD

Research Focus - Defining Replication Stress and Therapy Response Outcomes Regulated by the Fanconi Anemia/BRCA Pathway

  • Characterizing replication stress responses mediated by the Fanconi Anemia/BRCA pathway
  • Defining pathogenic mutations in hereditary breast/ovarian cancer genes
  • Defining and targeting replication stress suppression pathways in cancer
  • Understanding the mechanisms of therapy response and resistance in cancer

Representative Publication

Cong, K, Peng, M, Koushelt, AN, et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021;81(15):3128-3144.e7.

Read Publication

More Publications

In the News

Getting Results…
  • Convocation 2023: Chancellor Collins celebrates symphony of collaboration at UMass Chan

    Convocation 2023: Chancellor Collins celebrates symphony of collaboration at UMass Chan

    Four faculty members were honored with chancellor’s medals and four others were invested as endowed professors at the Convocation and Investiture ceremony at UMass Chan Medical School.

    Read more
  • Convocation events 2023

    UMass Chan celebrates start of new academic year with Convocation week

    The festivities begin on Friday, Sept. 8 with the annual White Coat Ceremony, welcoming the new T.H. Chan School of Medicine students into the medical community.

    Read more
  • Sharon Cantor and Andres Schanzer appointed to endowed chairs

    Sharon Cantor and Andres Schanzer appointed to endowed chairs

    The University of Massachusetts Board of Trustees voted to approve one new endowed chair at UMass Chan Medical School and the appointment of two accomplished faculty members to endowed chairs.

    Read more
  • Communicating science: Sharon Cantor discusses drug resistance in breast, ovarian cancer

    Communicating science: Sharon Cantor discusses drug resistance in breast, ovarian cancer

    Research by Sharon Cantor, PhD, into how chemotherapy works in inherited breast and ovarian cancer overturned a long-held model in the field and will play a key role in developing successful therapies.

    Read more
  • Cantor lab rethinks how common chemotherapy drug used in breast and ovarian cancer works

    Cantor lab rethinks how common chemotherapy drug used in breast and ovarian cancer works

    Research from the lab of Sharon Cantor, PhD, provides a new understanding of a PARP inhibitor, a chemotherapy drug commonly used against breast and ovarian cancer.

    Read more
  • For GSBS class speaker Sumeet Nayak science brings hope

    For GSBS class speaker Sumeet Nayak science brings hope

    Sumeet Nayak’s research in the lab of Sharon B. Cantor, PhD, has led to a renewed understanding of how cancer develops and has opened up avenues to effectively advance anti-cancer therapies.

    Read more
  • UMass Chan researchers forging new understanding of BRCA cancer gene function with NCI grant

    UMMS researchers forging new understanding of BRCA cancer gene function with NCI grant

    A UMass Medical School research team has been awarded a National Cancer Institute grant to advance understanding of how hereditary breast and ovarian cancer genes work, and why tumors lacking these genes are sensitive to chemotherapy.

    Read more